ProductsAbout UsContact UsSeminars

Indolplex® features bioavailable diindolylmethane for optimal hormone balance for both women and men

   50 and 100 VCAPS® (vegetable capsules)*#          

Indolplex® contains highly absorbable diindolylmethane (DIM), a natural indole from cruciferous sources. This protective phytonutrient promotes healthy hormone balance.


Practitioner Information

  • Indoles are natural phytonutrients found in cruciferous vegetables such as cabbage, Brussels sprouts, cauliflower and broccoli. These biologically active compounds are associated with a lower risk of major health issues.[1] DIM is the most abundant and active dietary indole derived from cruciferous vegetables.[2]
  • Indolplex® contains bioavailable DIM, a unique and highly absorbable diindolylmethane with demonstrated clinical activity[2],[3],[4],[5]
  • Indolplex® is not phytoestrogenic and has no inherent oestrogenic activity. Indolplex® assists the favourable metabolism of oestrogen down the 2-hydroxylation pathway.[2],[3],[4] A beneficial shift in metabolism can help maintain healthy oestrogen ratios and reduce the symptoms of oestrogen dominance.
  • The active 2-hydroxyoestrone metabolites are considered the ‘good’ oestrogens.[6] Whereas the 4-hydroxyoestrone and 16-alpha-hydroxyoestrone metabolites are often termed the ‘bad’ oestrogens. The common symptoms of oestrogen dominance are often due to underactive oestrogen metabolism and the overproduction of unfavourable oestrogen metabolites.
  • Indolplex® may be beneficial in symptoms associated with pre-menstrual syndrome (PMS) and medically diagnosed conditions such as fibrocystic breast disease, polycystic ovarian syndrome (PCOS), uterine fibroids, cyclical mastalgia 5 and cervical dysplasia.[7],[8]
  • Indolplex® may assist health of the reproductive tract [1],[2],[9] and breast in women.[4],[10],[11],[12]
  • Indolplex® may assist symptoms of medically diagnosed prostate disorders.[13],[14],[15]
  • Indolplex® may assist the metabolic changes observed in obesity in both men and women. Obesity, often considered an oestrogen excess condition is associated with an increased incidence of reproductive dysfunction and oestrogen linked disorders.[16]

Obesity is also associated with a significant reduction in 2-hydroxylation of oestrogen.[17] This metabolic alteration could further aggravate a relative hyperoestrogenic state.[16],[17] Unlike other oestrogen metabolites, the 2-hydroxyoestrogen compounds display relatively little peripheral oestrogenic activity.[16]  When used in conjunction with a nutritious diet and regular exercise Indolplex® can support improvements in body composition.[18]

Each Vcap® Contains

Indolplex® 65mg

equiv. bioavailable DIM 20mg

Excipient Ingredients

Cellulose microcrystalline, hydroxypropyl methylcellulose (Vcap®), calcium hydrogen phosphate, magnesium stearate (vegetable source) and silicon dioxide.

Directions For Use

Women: Take 2 capsules once to twice daily or as directed by your healthcare practitioner.

Men: Take 2 capsules twice daily or as directed by your healthcare practitioner.


  • Do not use Indolplex® if you are pregnant, may become pregnant or are lactating.

Precautions & Considerations

  • Harmless changes in urine colour may occur with Indolplex®. Increased water consumption can reduce this side effect.
  • Symptoms of nausea and/or headaches may occur with Indolplex®. Indolplex® assists activity of hepatic cytochrome P450 enzymes (CYP1A1) pathways. Nutrients required to support phase 2 liver detoxification pathways can assist in reducing these symptoms.
  • Indolplex® does not contain goitrogenic compounds which could affect thyroid function.
  • A short term increase in symptoms with Indolplex® may be due to increased metabolism of available oestrogen.
  • Indolplex® can be used in used in conjunction with phytoestrogenic herbs.
  • Indolplex® may assist hormone health when taken with Hormone Replacement Therapy (HRT)
  • Indolplex® may assist hormone health when taken with the oral contraceptive pill (OCP). Indolplex® has no inducing action on CYP3A4, the enzyme that metabolises the OCP. Therefore, Indolplex® does not affect efficacy of the OCP.
  • Indolplex® may assist effective metabolism of increased available oestrogen when taken with bioidentical hormone replacement therapy (BHRT).


[1] Sarkar FH, Li Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev. 2009 Nov;35(7):597-607. Epub 2009 Aug 5.
[2] Zeligs MA. Safer Estrogen With Phytonutrition. Townsend Letter for Doctors and Patients. 1999; 189:83-88.
[3] Zeligs, MA. The Cruciferous Choice: Diindolylmethane or I3C? Phytonutrient Supplements For Cancer Prevention and Health Promotion. Townsend Letterfor Doctors and Patients. August. 2001.
[4] Dalessandri KM, Firestone KM, Firestone GL, Fitch MD, et al. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition and Cancer. 2004;50(2):161-7.
[5] Zeligs MA, Brownstone PK, Sharp ME, et al. Managing Cyclical Mastalgia with Absorbable Diindolylmethane: A Randomized, Placebo-controlled Trial. JANA. Vol. 8, No.1 2005. Pages 10-20.
[6] Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-Hydroxyestrone: the 'good' estrogen. J Endocrinol. 1996;150 Suppl:S259-265.
[7] Chen DZ, Qi M, Auborn KJ, et al. Indole-3-Carbinol and Diindolylmethane Induce Apoptosis of Human Cervical Cancer Cells and in Murine HPV16-Transgenic Preneoplastic Cervical Epithelium. J Nutr. 2001 Dec;131(12):3294-3302.
[8] Zeligs MA, Sepkovic DW, Manrique C, et al. Absorption-enhanced 3,3’-Diindolylmethane: Human Use in HPV-related, Benign and Pre-cancerous Conditions. Proc. Am. Assoc. Cancer Res. 2003, Apr; 44.
[9] Leong H, Firestone GL, Bjeldanes LF. Cytostatic effects of 3,3'-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression. Carcinogenesis. 2001 Nov;22(11):1809-17.
[10] Rahman KW, Sarkar FH. Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Research 65. 2005 Jan 1;65(1):364-71.
[11] Rahman KW, Li Y, Wang Z, et al. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Research 6. 2006 May 1;66(9):4952-60.
[12] Miller, K. Estrogen and DNA Damage: The Silent Source of Breast Cancer? J Natl Cancer Inst. 2003 Jan 15;95(2):100-2.
[13] Zeligs, MA. The Doctor’s Research Update. Prostate Health Promotion with Diindolylmethane (DIM). 2008. Available at; Accessed May 1, 2008.
[14] Kong D, Yiwei L, Wang Z, et al. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Research 67. 2007 Apr 1;67(7):3310-9.
[15] Nachshon-Kedmi M, Yannai S, Fares FA. Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3'-diindolylmethane through the mitochondrial pathway. British Journal of Cancer (2004) 91, 13581363.
[16] Schneider J. Effects of obesity on estradiol metabolism: decreased formation of nonuterotropic metabolites. J Clin Endocrinol Metab. 1983 May;56(5):973-8.
[17] Hershcopf RJ, Bradlow HL. Obesity, diet, endogenous estrogens, and the risk of hormone-sensitive cancer. Am J Clin Nutr. 1987 Jan;45(1 Suppl):283-9.
[18] Zeligs, MA. The Doctor’s Research Update. Diindolylmethane (DIM) For Healthy Aging. 2008. Available at; Accessed May 1, 2008.
[19] Zeligs MA, Fulfs JC, Peterson R, et al. In vivo, uterine-protective activity of absorption-enhanced diindolylmethane: Animal and preliminary human use in combination with Tamoxifen. Proc Am Assoc Cancer Res. 2003. 44:1268.

* VCAPS and the VCAPS logo are trademarks used under license
# This product is available in Queensland only